A Multisite Trial of ACQUIREc Therapy

The University of Alabama at Birmingham

Status: Completed

Conditions: Hemiparetic Cerebral Palsy

Treatments: Other: Therapy services (ACQUIREc Therapy)

Study type: Interventional

Funder types: Other

Identifiers

NCT00991692

deluca-ms1

Details and patient eligibility

About

A multisite trial to testing different dosage levels of a systematic form of Pediatric Constraint-Induced (CI) Therapy called ACQUIREc Therapy. The high dosage treatment involved 6 hours of daily therapy services for 21 days. This was compared to a moderate dosage level of 3 hours of daily therapy services for 21 days. It was hypothesized that children receiving the higher therapy dosage would have greater and more clinically significant benefits from ACQUIREc Therapy but that both groups of children would benefit from the therapy services.

Enrollment: 18 patients

Sex: All

Ages: 3 to 8 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Children 3-6 years of age
• Hemiparetic CP

Exclusion criteria

• No prior CI therapy treatments
• No Botox for 6-months

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Factorial Assignment

Masking: Single Blind

---

18 participants in 1 patient group

Treatment dosage levels examined

Experimental group

Treatment:

Other: Therapy services (ACQUIREc Therapy)